Inhibrx, Inc. (NASDAQ:INBX) Sees Large Increase in Short Interest

Inhibrx, Inc. (NASDAQ:INBX) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,200,000 shares, an increase of 10.1% from the November 30th total of 1,090,000 shares. Based on an average trading volume of 77,600 shares, the short-interest ratio is presently 15.5 days. Approximately 12.1% of the shares of the stock are short sold.

Inhibrx Trading Up 1.7 %

Inhibrx stock opened at $15.40 on Thursday. The firm’s 50-day simple moving average is $15.10 and its 200 day simple moving average is $14.64. Inhibrx has a 52 week low of $10.80 and a 52 week high of $18.95.

Insider Buying and Selling

In other news, Director Jon Faiz Kayyem bought 69,686 shares of the stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $14.23 per share, with a total value of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 22.20% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.